Krystal Biotech Inc

NASDAQ:KRYSUnited States

Krystal Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of redosable gene therapies for patients living with debilitating diseases. It has developed a gene delivery platform that enables off-the-shelf treatments for serious dermatology and respiratory diseases. Its platform consists of an engineered viral vector derived from the herpes simplex virus type 1 (HSV-1) that it has optimized for local and repeat gene transfer to epithelial cells. Its product candidates in various stages of clinical and preclinical development include Vyjuvek for dystrophic epidermolysis bullosa (Dystrophic EB), KB105 for TGM1-deficient autosomal recessive congenital ichthyosis (ARCI), KB104 for Netherton Syndrome, KB407 for Cystic Fibrosis (CF), and KB408 for Alpha-1 antitrypsin deficiency (AATD). Its KB301 is for aesthetic skin conditions. Its subsidiary, Jeune Aesthetics, Inc, focuses on preclinical and clinical studies for aesthetic skin conditions.

Contact Information

Headquarters

2100 Wharton St Ste 701PITTSBURGH, PA, United States 15203-1973

Phone

412-586-5830

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Krish Krishnan

Founder, Chief Operating Officer, Director, President - Research and Development

Suma Krishnan

President - Jeune, Inc

Bhushan Hardas

Chief Accounting Officer

Kathryn Romano

Chief Business Officer

Jing Marantz